Physician profile
Adrian Lujan
NPI 1265043210
$2,608.17
in general payments reported to CMS, 2019-2025
18 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $546 · 2024: $898 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,508 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,508.18 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $465.01 | 2023-2025 | Opzelura |
| Janssen Biotech, INC. | $418.95 | 2023-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $219.46 | 2023-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $211.81 | 2023-2024 | Sotyktu |
| Abbvie INC. | $208.19 | 2023-2025 | |
| Ucb, INC. | $168.94 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $164.62 | 2024-2025 | Nemluvio |
| Organon LLC | $163.01 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $126.09 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $96.63 | 2025 | |
| Novartis Pharmaceuticals Corporation | $78.86 | 2025 | |
| Lilly USA, LLC | $75.52 | 2024 | Olumiant, Taltz, Zepbound |
| Leo Pharma INC. | $60.08 | 2024 | Adbry |
| Arcutis Biotherapeutics, INC. | $59.86 | 2024-2025 | Zoryve |
| Amgen INC. | $45.07 | 2023-2024 | Otezla |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $18.77 | 2025 | Vyjuvek |
| Helsinn Therapeutics (U.S.), INC. | $14.16 | 2023 | Valchlor |
| Dermavant Sciences, INC. | $13.14 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Lujan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.